About DRUGS FOR NEGLECTED DISEASES INITIATIVE - REGIONAL OFFICE

The Drugs for Neglected Diseases initiative (DNDi) is an international, not-for-profit research and development (R&D) organization that develops and delivers new treatments for neglected diseases that affect millions of the world’s poorest people.

Together with more than 200 public research and industry allies worldwide, we use the power of partnership, innovation, open science, and advocacy to find solutions to a great injustice: the lack of medicines for life-threatening diseases that disproportionately impact poor and marginalized people. Driven by collaboration, not competition, and by patients’ needs, not profits, we promote equitable access, foster inclusive and sustainable solutions, and advocate for a more effective global biomedical R&D system that meets the needs of neglected patients.

Since our inception, DNDi has delivered 12 new treatments for people with sleeping sickness, visceral leishmaniasis, Chagas disease, HIV, hepatitis C, and malaria that have saved millions of lives. We now aim to deliver an additional 15-18 new treatments by 2028 – addressing R&D gaps for neglected tropical diseases and viral infections, including new pandemic-prone diseases (such as Covid-19) and climate-sensitive diseases (such as dengue) with a focus on the needs of patients in low- and middle-income countries.

With 250 employees of 37 nationalities located in nine offices on four continents, DNDi is committed to diversity, equity, and inclusion as essential parts of our culture and key drivers of our success. We encourage candidates of diverse profiles and backgrounds to apply.

Counting the Malaysia Ministry of Health as a founding member, DNDi was established in Kuala Lumpur in 2004. An integral part of DNDi’s global network, DNDi South-East Asia develops and supports R&D and access partnerships in the broad region, including for hepatitis C and Dengue, while contributing to the global strategy. The successful registration of ravidasvir in 2021 as the first affordable hepatitis C treatment paved the way for further collaborations in Malaysia, Thailand and beyond.